3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
12
Carcinoma, Hepatocellular
7
Colorectal Neoplasms
5
Neoplasm Metastasis
4
Esophageal Squamous Cell Carcinoma
4
Advanced Solid Tumor
4
Solid Tumor
3
Small Cell Lung Carcinoma
3
Esophageal Neoplasms
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Melanoma
2
Lung Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Transitional Cell
2
Advanced Solid Tumour
2
Unresectable Stage III Non-small Cell Lung Cancer
1
Triple Negative Breast Neoplasms
1
Skin Neoplasms
1
Simpson-Golabi-Behmel syndrome
1
Rectal Neoplasms
1
Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal Metastasis
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Nasopharyngeal Carcinoma
1
Metastatic Solid Tumors
1
MSI-H/dMMR Solid Tumors
1
Interventions
Rituximab
41
Cyclophosphamide
36
Prednisone
24
Doxorubicin
23
Magnetic Resonance Spectroscopy
20
Vincristine
19
Lenalidomide
18
Gemcitabine
18
Specimen Handling
17
Biopsy
15
Oxaliplatin
14
polatuzumab vedotin
13
obinutuzumab
11
glofitamab
11
ibrutinib
10
fludarabine
8
Etoposide
8
Dexamethasone
8
CT-P10
8
prednylidene
7
deltacortene
7
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
7
venetoclax
6
tafasitamab
6
pembrolizumab
6
Prednisolone
6
fludarabine phosphate
5
acalabrutinib
5
R-CHOP protocol
5
Cyclosporine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Lymphoma, Large B-Cell, Diffuse
×
tislelizumab
×
90 days
×
Clear all
No trials found.